✦ LIBER ✦

Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients

✍ Scribed by Rodrigo Ruiz-Soto; Guillaume Sergent; Christian Gisselbrecht; Jerome Larghero; Marjan Ertault; Christophe Hennequin; Julien Manson; Eric de Kerviler; Josette Briere; Nicolas Mounier

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 103 KB
Volume: 104
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.21492

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Allogeneic stem cell transplantation in

Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation

✍ Ji-Won Kim; Byung-Su Kim; Soo-Mee Bang; Inho Kim; Dong Hwan Kim; Won Seog Kim; D 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 197 KB

Rituximab long-term maintenance therapy

Rituximab long-term maintenance therapy after autologous stem cell transplantation in patients with B-cell non-Hodgkin’s lymphoma

✍ Frank Neumann; Stefani Harmsen; Simona Martin; Ralf Kronenwett; Mustafa Kondakci 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 96 KB

Therapeutic results in patients with rel

Therapeutic results in patients with relapsed diffuse large B cell Non-Hodgkin's lymphoma achieving complete response only after autologous stem cell transplantation

✍ Felicetto Ferrara; Assunta Viola; Carolina Copia; Ettore Mariano Schiavone; Mari 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

## Abstract Forty patients with relapsed diffuse large B cell lymphoma (DLBCL) autografted in partial response (PR) (__n__ = 23) or in refractory relapse (RR) (__n__ = 17) achieved complete remission (CR) after autologous stem cell transplantation (ASCT). Salvage treatment consisted of ifosphamide,